Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab.

Publikation

Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab.

Wissenschaftlicher Artikel/Review - 25.08.2022

Rubbert-Roth Andrea, Furst Daniel E, Fiore Stefano, Praestgaard Amy, Bykerk Vivian, Bingham Clifton O, Charles-Schoeman Christina, Burmester Gerd R

Zitation

Rubbert-Roth A, Furst D, Fiore S, Praestgaard A, Bykerk V, Bingham C, Charles-Schoeman C, Burmester G. Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab. Arthritis Res Ther 2022; 24:207.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Arthritis Res Ther 2022; 24

Veröffentlichungsdatum

25.08.2022

eISSN (Online)

1478-6362

Seiten

207

Kurzbeschreibung/Zielsetzung

Anemia is common in patients with rheumatoid arthritis (RA). Higher hemoglobin (Hb) levels may be associated with better clinical outcomes and patient-reported outcomes (PROs). To assess this hypothesis, we conducted two post hoc analyses in three sarilumab phase III studies: TARGET, MOBILITY, and MONARCH.